Reimbursed Care Access in Virgin Islands (British)

Currently classified as a strictly controlled substance under the Territory’s Drugs (Prevention of Misuse) Act; the statute explicitly lists psilocin (the active metabolite of psilocybin) among controlled substances, and the Act’s licensing and practitioner exemptions are the only paths for lawful medical supply or possession. There is no public reimbursement framework or specific medical/therapeutic program for psilocybin in the BVI; any lawful use would need to be under the Act’s research or ministerial authorisation provisions. #

Currently classified as a strictly controlled substance under the Territory’s Drugs (Prevention of Misuse) Act, which either names specific hallucinogens or covers broad phenethylamine/amphetamine-derived classes that include MDMA analogues; there is no authorised medical/insured access or reimbursement pathway for MDMA outside of formally approved research under the Act. #

Esketamine (marketed forms such as SPRAVATO®) is not described in any BVI public reimbursement program and there is no evidence of a territory-wide, publicly funded esketamine clinic network or specific coverage policy; however, the Drugs (Prevention of Misuse) Act provides the Minister with power to make regulations and to authorise lawful supply/administration of controlled drugs by doctors, dentists, veterinary practitioners and licensed pharmacies under terms and conditions set by regulation, meaning that licensed practitioners could lawfully prescribe/administer controlled medicines in a clinical context when permitted by regulation. There is no publicly available BVI Ministry of Health reimbursement policy or statutory schedule that establishes esketamine on a reimbursed formulary as of the Act consolidation (Revised 2020). Any introduction of an esketamine program would therefore require ministerial/regulatory steps and local clinic accreditation/licensing under the Act. #

Ketamine as an accepted anaesthetic and analgesic is routinely used worldwide and, within the BVI legal framework, supply/administration of controlled drugs by a doctor, dentist or licensed pharmacy is rendered lawful when done in accordance with the Act’s regulatory provisions and any licences/conditions issued by the Minister; the Act therefore allows medical (professional) use of controlled drugs under regulation, but the territory does not publish a specific public reimbursement program for ketamine-based psychiatric treatments. In short: ketamine can be administered lawfully by authorised practitioners under the Act’s licensing/regulatory regime, but there is no evidence of a dedicated, publicly reimbursed ketamine-for-psychiatry program in the BVI. #

Currently classified as a strictly controlled substance under the Territory’s controlled-substances schedules: the consolidated Act text lists N,N‑Dimethyltryptamine (DMT) and other tryptamine derivatives among controlled drugs; there is no authorised medical or reimbursement pathway for DMT outside of approved research or specific Ministerial authorisations. #

5‑MeO‑DMT falls within the Act’s coverage of tryptamine-derived controlled substances and related analogues; accordingly, it is a strictly controlled substance in the Territory with no authorised medical use or reimbursement except under the limited research/ministerial-authorisation pathways provided by the Act. #

Ibogaine is not provided a specific medical/regulatory program in the BVI and is covered by the Act’s controls on psychoactive substances and analogous compounds; there is no authorised, reimbursed clinical program for ibogaine in the Territory and lawful use would only be possible through expressly authorised research or ministerial licence. #

Ayahuasca contains DMT and other regulated constituents; the Act’s listing of DMT and related tryptamine classes means ayahuasca preparations are effectively controlled. There is no authorised traditional/religious exemption or reimbursed medical program for ayahuasca in the BVI; lawful use would require explicit regulatory or ministerial authorisation or be limited to approved research. #

Mescaline is explicitly named among controlled substances in the consolidated Drugs (Prevention of Misuse) Act schedule; sale, supply and possession outside authorised medical, licensed or research channels is unlawful and there is no public reimbursement or medical program for mescaline-based therapy in the BVI. (Note: many statutes differentiate extracts/alkaloids from whole plants; the Act explicitly lists mescaline itself.) #

The Act includes broad coverage for phenethylamine-derived compounds and lists a range of substituted phenethylamines and related classes; 2C‑series compounds (2C‑X) fall within those controlled phenethylamine/amphetamine groupings and are therefore strictly controlled with no authorised medical/reimbursed use outside of approved research. #